Paradigm Biopharmaceuticals Limited (PBIGF)
USD 0.13
(-62.83%)
USD 0.13
(-62.83%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -65.11 Million AUD | -25.47% |
| 2023 | -51.89 Million AUD | -32.31% |
| 2022 | -39.22 Million AUD | -14.48% |
| 2021 | -34.25 Million AUD | -179.33% |
| 2020 | -12.26 Million AUD | -144.14% |
| 2019 | -5.02 Million AUD | 43.82% |
| 2018 | -8.94 Million AUD | -45.61% |
| 2017 | -6.14 Million AUD | -42.12% |
| 2016 | -4.32 Million AUD | -174.77% |
| 2015 | -1.57 Million AUD | -579.51% |
| 2014 | -231.43 Thousand AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -7.48 Million AUD | 85.0% |
| 2024 Q2 | -49.89 Million AUD | -98.99% |
| 2024 Q1 | -25.07 Million AUD | 6.86% |
| 2024 Q4 | -7.48 Million AUD | 0.0% |
| 2024 FY | -64.49 Million AUD | -24.28% |
| 2023 Q2 | -32.29 Million AUD | -97.18% |
| 2023 Q4 | -26.91 Million AUD | -99.44% |
| 2023 Q1 | -16.37 Million AUD | 17.09% |
| 2023 FY | -51.89 Million AUD | -32.31% |
| 2023 Q3 | -13.49 Million AUD | 58.21% |
| 2022 Q2 | -27.25 Million AUD | -96.97% |
| 2022 Q4 | -19.75 Million AUD | -95.07% |
| 2022 FY | -39.22 Million AUD | -14.48% |
| 2022 Q3 | -10.12 Million AUD | 62.84% |
| 2022 Q1 | -13.83 Million AUD | 35.63% |
| 2021 Q4 | -21.49 Million AUD | -93.54% |
| 2021 FY | -34.25 Million AUD | -179.33% |
| 2021 Q1 | -10.48 Million AUD | 5.08% |
| 2021 Q2 | -20.84 Million AUD | -98.86% |
| 2021 Q3 | -11.1 Million AUD | 46.72% |
| 2020 Q3 | -5.93 Million AUD | -0.33% |
| 2020 FY | -12.26 Million AUD | -144.14% |
| 2020 Q2 | -5.91 Million AUD | -132.45% |
| 2020 Q1 | -2.54 Million AUD | 66.14% |
| 2020 Q4 | -11.04 Million AUD | -86.08% |
| 2019 Q4 | -7.51 Million AUD | -229.64% |
| 2019 Q1 | -2.2 Million AUD | -64.75% |
| 2019 Q2 | -2.2 Million AUD | 0.0% |
| 2019 Q3 | -2.28 Million AUD | -3.63% |
| 2019 FY | -5.02 Million AUD | 43.82% |
| 2018 Q3 | -1.33 Million AUD | 25.25% |
| 2018 FY | -8.94 Million AUD | -45.61% |
| 2018 Q4 | -1.33 Million AUD | 0.0% |
| 2018 Q2 | -1.78 Million AUD | 0.0% |
| 2018 Q1 | -1.78 Million AUD | -141.0% |
| 2017 Q3 | -741.32 Thousand AUD | 47.39% |
| 2017 Q2 | -1.4 Million AUD | 0.0% |
| 2017 Q1 | -1.4 Million AUD | -75.55% |
| 2017 FY | -6.14 Million AUD | -42.12% |
| 2017 Q4 | -741.32 Thousand AUD | 0.0% |
| 2016 Q1 | -711.27 Thousand AUD | 3.4% |
| 2016 Q3 | -802.72 Thousand AUD | -12.86% |
| 2016 Q4 | -802.72 Thousand AUD | 0.0% |
| 2016 FY | -4.32 Million AUD | -174.77% |
| 2016 Q2 | -711.27 Thousand AUD | 0.0% |
| 2015 Q2 | -305.13 Thousand AUD | 0.0% |
| 2015 Q4 | -736.32 Thousand AUD | 0.0% |
| 2015 FY | -1.57 Million AUD | -579.51% |
| 2015 Q1 | -305.13 Thousand AUD | 0.0% |
| 2014 FY | -231.43 Thousand AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Qrons Inc. | -643.67 Thousand USD | -10015.661% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 179.549% |
| Nascent Biotech, Inc. | -2.22 Million USD | -2819.987% |
| Adynxx, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -310.292% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -5084.091% |
| BioStem Technologies, Inc. | -7.77 Million USD | -737.028% |
| CSL Limited | 3.7 Billion USD | 101.759% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -1190.76% |
| Evofem Biosciences, Inc. | -17.84 Million USD | -264.835% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | -17.302% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -9378.446% |
| Skye Bioscience, Inc. | -13.67 Million USD | -376.252% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -15571.594% |
| Rebus Holdings, Inc. | -664 Thousand USD | -9706.052% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -4775.743% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -16613.859% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 9.297% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 1424.816% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -24777.995% |
| SQZ Biotechnologies Company | -75.82 Million USD | 14.128% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -2184.232% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -4138.939% |
| Mesoblast Limited | -84.14 Million USD | 22.621% |
| Marizyme, Inc. | -34.08 Million USD | -91.02% |
| Genus plc | 6.4 Million USD | 1117.378% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 768.334% |
| Pharming Group N.V. | -4.87 Million USD | -1234.391% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -3177.768% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -6890.936% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -679.787% |
| ContraFect Corporation | -56.88 Million USD | -14.455% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -1329.552% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -4544.265% |
| IMV Inc. | -38.67 Million USD | -68.372% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -2266.994% |
| MultiCell Technologies, Inc. | -722.81 USD | -9008101.602% |
| ONE Bio Corp. | 13.68 Million USD | 575.912% |
| Accustem Sciences Inc. | -3.74 Million USD | -1637.985% |
| RVL Pharmaceuticals plc | -58.99 Million USD | -10.378% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -13379.053% |
| Q BioMed Inc. | -3.44 Million USD | -1789.711% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 1939.327% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -2378.083% |
| Biomind Labs Inc. | -1 Million USD | -6349.286% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | -18.445% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -2144.28% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -879.423% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -3392.45% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -217288.428% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -3269.132% |
| GB Sciences, Inc. | -1.42 Million USD | -4483.722% |
| Alpha Cognition Inc. | -9.7 Million USD | -570.872% |
| HST Global, Inc. | -140.9 Thousand USD | -46109.331% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -5688.233% |
| Halberd Corporation | -75.05 Thousand USD | -86658.404% |
| Enzolytics Inc. | -2.14 Million USD | -2930.165% |
| Agentix Corp. | -1.37 Million USD | -4646.63% |
| Resverlogix Corp. | -12.74 Million USD | -410.724% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -1955.131% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 84.681% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -6136.799% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -2130.294% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -4022.707% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -1812.264% |
| AVAX Technologies, Inc. | 6.69 Million USD | 1072.857% |
| Zenith Capital Corp. | -8.94 Million USD | -628.08% |
| Genscript Biotech Corporation | -415.79 Million USD | 84.34% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -373656.857% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -2551.885% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -37864.175% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -3147.884% |
| Kadimastem Ltd | -3.04 Million USD | -2041.672% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -6516.735% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -35777.446% |
| LadRx Corporation | -3.82 Million USD | -1602.891% |
| Cell Source, Inc. | -4.32 Million USD | -1405.364% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -9378.446% |
| NovAccess Global Inc. | -2.46 Million USD | -2539.583% |
| Affymax, Inc. | -15.04 Million USD | -332.754% |
| Itoco Inc. | -919.14 Thousand USD | -6984.033% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -1436.239% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -5718.783% |
| Mobile Lads Corp. | -554.55 Thousand USD | -11641.445% |
| CytoDyn Inc. | -18.05 Million USD | -260.572% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -258589.638% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -29485.957% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -11429.933% |
| SYBLEU INC | -149.18 Thousand USD | -43546.723% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -3484.841% |
| International Stem Cell Corporation | -663 Thousand USD | -9720.842% |
| Bioxytran, Inc. | -3.82 Million USD | -1604.442% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -123593.355% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -320018.889% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | -79.541% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -3924.239% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -8748.748% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -1992.966% |
| Neutra Corp. | -229.48 Thousand USD | -28273.052% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -271.242% |
| PureTech Health plc | -146.19 Million USD | 55.463% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | -202.972% |
| IXICO plc | -1.43 Million USD | -4431.119% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -586.041% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 46.544% |
| CSL Limited | 3.81 Billion USD | 101.708% |
| Cellectis S.A. | -108.85 Million USD | 40.186% |